Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04176952
Other study ID # PRIMUS0022016
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date March 5, 2019
Est. completion date August 19, 2021

Study information

Verified date May 2022
Source University of Glasgow
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

PRIMUS 002 is looking at 2 different chemotherapy regimens in the neo-adjuvant setting for pancreatic cancer. Each treatment will be given for 3 months prior to surgery


Description:

This is an integrated, open label, non-randomised, phase II trial of 2 neo-adjuvant regimens (FOLFOX-A and AG) assessing efficacy and toxicity with integrated translational work. The study is powered on testing a proposed DNA damage response deficient biomarker for responsiveness in patients treated with FOLFOX-A; patients being treated with AG are recruited concurrently. The study has a prospective safety assessment of neo-adjuvant chemotherapy and neo-adjuvant chemotherapy followed by chemoradiotherapy consisting of conventional radiotherapy with concomitant capecitabine. This safety assessment will include all patients (FOLFOX-A and AG)


Recruitment information / eligibility

Status Terminated
Enrollment 31
Est. completion date August 19, 2021
Est. primary completion date August 19, 2021
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: 1. Patient has been enrolled in the Precision-Panc Master Protocol and their tissue has been deemed suitable for Next Generation Sequencing analysis (a Precision-Panc Master Protocol identifier will be required at the time of study enrolment) 2. Signed informed consent given for PRIMUS 002 study 3. Age = 16 years 4. Resectable or borderline resectable pancreatic cancer as defined by National Comprehensive Cancer Network criteria following discussion at the Multi Disciplinary Team 5. Measurable Disease as per RECIST 1.1 6. Histological or cytologically proven pancreatic ductal adenocarcinoma (including variants) 7. Able to undergo biliary drainage using a covered or partially covered self-expanding metal stent if jaundiced 8. Eastern Cooperative Oncology Group performance status 0 and 1 9. Adequate liver/bone marrow function as defined by: 1. Neutrophils (ANC) = 1.5 x 109/l 2. Platelets = 100 x 109/l 3. Haemoglobin = 9.0g/dL 4. White Blood Cells (WBC) = 3 x 109/l 5. Total bilirubin = 1.5 x institutional upper limit of normal (ULN) unless bilirubin rise is due to Gilbert's syndrome 6. Aspartate transaminase (AST) and alanine aminotransferase (ALT) = 2.5 x ULN (or <5 x ULN in the presence of liver metastases) 7. Estimated creatinine clearance = 60 mL/min (as calculated by Cockcroft and Gault or Wright formula or measured by EDTA clearance) 10. Negative serum Human Chorionic Gonadotropin (HCG) test for females with child bearing potential. Postmenopausal women must have been amenorrhoeic for at least 12 months to be considered of non-childbearing potential 11. Woman of child bearing potential, and men with female partners of child bearing potential, must agree to use adequate contraceptive measures (see section 7.1.11.1) for the duration of the study and for up to 6 months after the completion of study treatment. 12. Able to comply with protocol requirements and deemed fit for surgical resection, chemotherapy and CRT Exclusion Criteria: 1. Distant metastatic disease 2. History of previous or concurrent malignancy diagnosis (except curatively treated basal cell carcinoma of skin or carcinoma in situ of cervix) in the last 3 years 3. Prior chemotherapy or CRT for pancreatic cancer 4. Known hypersensitivity for any component of any study drug 5. Active infection including Herpes Zoster and chickenpox 6. Uncontrolled congestive heart failure (CHF), or history of myocardial ischemia (MI), unstable angina, stroke, or transient ischemia within previous 6 months. 7. Serious medical or psychological condition precluding neo-adjuvant treatment and surgical resection 8. New York Heart Association Classification Grade III or IV 9. Liver cirrhosis (except for Child-Pugh A) 10. Major surgery within 28 days prior to trial entry 11. Any patients receiving treatment with brivudin, sorivudin and analogues or patients who have not stopped these drugs at least 4 weeks prior to the start of study treatment 12. Any patient with severe diarrhoea (defined as =grade 3 diarrhoea despite maximum supportive measures and exclusion of underlying infection) 13. Patients with known malabsorption 14. Patients with known or suspected dihydropyrimidine dehydrogenase (DPD) deficiency 15. Grade = 2 peripheral neuropathy 16. Administration of any investigational drug within 28 days or 5 half-lives, whichever is longer, prior to receiving the first dose of trial treatment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
FOLFOX-A
nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first). Oxaliplatin: 85mg/m2, IV over 2 hours, day 1. Folinic acid: 350mg flat dose, IV over 2 hours, day 1. Fluorouracil infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours or 48 hours as per local practice.)
AG
nab-paclitaxel: 125mg/m2 IV over 30 minutes on days 1, 8 and 15 (administered first). Gemcitabine 1000mg/m2 IV over 30 minutes on days 1, 8 and 15 (immediately following nab-paclitaxel).

Locations

Country Name City State
United Kingdom Western General Edinburgh
United Kingdom Beatson West of Scotland Cancer Centre Glasgow
United Kingdom Royal Free Hospital London

Sponsors (3)

Lead Sponsor Collaborator
Judith Dixon-Hughes NHS Greater Glasgow and Clyde, University of Glasgow

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to progression post FOLFOX-A induction treatment date of progression after FOLFOX-A neo-adjuvant chemotherapy as assessed by RECIST 1.1 CT scans will take place at baseline, pre chemoradiotherapy and pre surgery, over approximately 6 months
Secondary Proving liquid biopsies can be used to define patient subgroups a liquid biopsy will be taken and analysed using circulating tumour DNA at different timepoints to see if these can be used to define patient subgroups From date of registration to date of surgery. On average 4 months after registration
Secondary Response post neo-adjuvant chemotherapy CT scans will be reported to RECIST 1.1 and best response will be evaluated CT scan will be performed at baseline and then post neo-adjuvant chemotherapy (approximately 3 months later)
Secondary College of American Pathologists tumour regression grade CAP tumour regression grade (grade 0-3 with 0 being no viable residual tumour and 3 being poor to no response) will be assessed post surgery Post surgery which will be approximately 4 months post registration
Secondary R0 rate post surgery R0 rate will be assessed post surgery Post surgery which will be approximately 4 months post registration
Secondary Overall survival Overall survival will be assessed in all patients From date of registration until date of death assessed for up to 5 years post registration
Secondary Disease free survival Disease free survival will be assessed at every follow up visit from date of registration until date of disease recurrence assessed for at least 24 months post registration
Secondary Safety and tolerability of study drugs: NCI CTCAE 4.03 Safety and tolerability will be assessed as per NCI CTCAE 4.03 Assessed at every clinic visit during treatment, for approximately 3 months post registration
Secondary Safety and tolerability of chemoradiotherapy: NCI CTCAE 4.03 Safety and tolerability of chemoradiotherapy will be assessed as per NCI CTCAE 4.03 Assessed at every chemoradiotherapy visit and pre-surgery (once Chemoradiotherapy added). Chemoradiotherapy will take place 5 days a week for three weeks
Secondary Surgical complication rate Rate of surgical complication as assessed by NCI CTCAE 4.03 Assessed post surgery, approximately 4 months post registration
Secondary Neurotoxicity Assessed by GOG NTX4 (4 questions graded from 0 (not at all) to 4 (very much). quality of life will be assessed using the GOG NTX4 tool at the following timepoints: Baseline, month 1, month 2, month 3, pre chemoradiotherapy, between fraction 11 and 15 of chemoradiotherapy, pre surgery, at every follow-up visit (6, 9, 12 months post registration then every 6 months) Neurotoxicity will be assessed from registration until study is completed at various timepoints until patient death. Each patient will be followed up for at least 24 months post registration
Secondary Quality of life assessed by EORTC QLQ-C30 quality of life will be assessed using the EORTC QLQ C30 tool at the following timepoints: Baseline, month 1, month 2, month 3, pre chemoradiotherapy, between fraction 11 and 15 of chemoradiotherapy, pre surgery, at every follow-up visit (6, 9, 12 months post registration then every 6 months for a minimum of 24 months). The Quality of life tool is comprised of 28 questions that the patient answers either 1-4 (1 = not at all, 4 = Very much) and 2 questions that are on al scale of 1 - 7 where 1 = very poor and 7 = excellent Quality of life will be assessed from registration until study is completed at various timepoints until patient death. Each patient will be followed up for at least 24 months post registration
Secondary Quality of life assessed by EORTC QLQ-PAN26 quality of life will be assessed using the EORTC QLQ-PAN26 tool at the following timepoints: Baseline, month 1, month 2, month 3, pre chemoradiotherapy, between fraction 11 and 15 of chemoradiotherapy, pre surgery, at every follow-up visit (6, 9, 12 months post registration then every 6 months for a minimum of 24 months). The Quality of life tool is comprised of 26 questions that the patient answers either 1-4 (1 = not at all, 4 = Very much) Quality of life will be assessed from registration until study is completed at various timepoints until patient death. Each patient will be followed up for at least 24 months post registration
Secondary Health Economics Health economics defined as number of visits to hospital per patient, both as an inpatient and as an outpatient will be assessed at the following timepoints: Baseline, month 1, month 2, month 3, pre chemoradiotherapy, between fraction 11 and 15 of chemoradiotherapy, pre surgery, at every follow-up visit (6, 9, 12 months post registration then every 6 months for a minimum of 24 months) Health economics will be assessed from registration until study is completed at various timepoints until patient death. Each patient will be followed up for at least 24 months post registration
See also
  Status Clinical Trial Phase
Terminated NCT01313416 - Gemcitabine and CT-011 for Resected Pancreatic Cancer Phase 2
Completed NCT05547074 - A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma
Withdrawn NCT03245658 - The Effect of Cannabis in Pancreatic Cancer Phase 2
Completed NCT02973217 - Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer N/A
Recruiting NCT04151277 - PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer Phase 2
Recruiting NCT04161417 - Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer N/A
Terminated NCT03187587 - Percutaneous Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer N/A
Recruiting NCT05669482 - Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer Phase 1/Phase 2
Completed NCT03535727 - A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT04566614 - Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies
Completed NCT06118125 - Delay to Diagnosis in Digestive Cancerology by the General Practitioner Related to Covid-19 Pandemic Confinement
Active, not recruiting NCT03678883 - 9-ING-41 in Patients With Advanced Cancers Phase 2